Thalia Therapeutics PLC
0GO
Company Profile
Business description
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.
Contact
2 Portman Street
LondonW1H 6DU
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,755.70 | 62.80 | -0.71% |
| CAC 40 | 7,952.55 | 129.72 | -1.61% |
| DAX 40 | 23,950.57 | 505.69 | -2.07% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,195.37 | 177.56 | -1.71% |
| HKSE | 25,620.76 | 341.97 | -1.32% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 60,843.09 | 566.20 | -0.92% |
| NZX 50 Index | 12,815.92 | 149.09 | -1.15% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,526.00 | 51.90 | -0.61% |
| SSE Composite Index | 4,136.62 | 1.23 | 0.03% |